Crystalys Therapeutics
Crystalys Therapeutics develops dotinurad, an oral URAT1 inhibitor for treating gout
$130MSeries B
Role not disclosedFL
Frazier Life Sciences
Activity from announced rounds
Activity in this selectionnomura-real-estate-development-co-f095adde
- Rounds participated in
- 5
- Confirmed lead rounds
- — 5 roles undisclosed
- New companies
- 5 First participation on record · 0 follow-on
- Funding in participating rounds
- $887M 5 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
5 in this selectionRQ Bio
Develops antibody therapies to prevent seasonal influenza in high-risk and immunocompromised patients
$115MSeries A
Role not disclosedSidewinder Therapeutics
Develops next-generation bispecific ADCs for cancer treatment
$137MSeries B
Role not disclosedAirNexis Therapeutics
AirNexis Therapeutics develops medicines for pulmonary diseases, led by the investigational COPD candidate AN01.
$200MSeries A
Role not disclosedParabilis Medicines
Develops medicines targeting historically undruggable protein targets in cancer
$305MSeries F
Role not disclosed